Filing Flows › iSpecimen (ISPC) › Q2 2026 › vs Q2 2025
iSpecimen (ISPC) Q2 2026 vs Q2 2025 (year over year)
iSpecimen's revenue fell $561K (-79%) from $713K in Q2 2025 to $152K in Q2 2026. The biggest changes: Product −$546K (-81%); Shipping and Handling −$15K (-36%).
iSpecimen, Q2 2026: revenue $152K (-79% year over year), operating margin -897.1%, net loss $1.4M, operating cash flow −$690K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $125K | $672K | −$546K | -81% |
| Shipping and Handling | $27K | $41K | −$15K | -36% |
| Revenue | $152K | $713K | −$561K | -79% |
| Net loss | $1.4M | $1.0M | $316K | +30% |
| Costs & expenses | $1.5M | $2.5M | −$1.0M | -40% |
| Operating costs | $1.5M | $2.5M | −$1.0M | -40% |
| Cost of revenue | $83K | $396K | −$313K | -79% |
| Sales & marketing | $544K | $258K | $286K | +111% |
| General & admin | $443K | $948K | −$506K | -53% |
| Other operating costs | $445K | $932K | −$487K | -52% |
| Operating cash sources | $1.4M | $1.0M | $316K | +30% |
| Depreciation & amortization | $201K | $433K | −$231K | -53% |
| Share-based compensation | $153 | $2K | −$2K | -92% |
| Working capital & other | $472K | $420K | $51K | +12% |
| Cash used in operations | $690K | $192K | $497K | +259% |
| Net loss absorbed | $1.4M | $1.0M | $316K | +30% |
Questions
How much did iSpecimen's revenue grow year over year in Q2 2026?
iSpecimen's revenue fell $561K (-79%) from $713K in Q2 2025 to $152K in Q2 2026.
What drove iSpecimen's revenue change in Q2 2026?
Product −$546K (-81%); Shipping and Handling −$15K (-36%).